Shilpa Medicare L News

Compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

US Approval for Varenicline Tablets, 0.5 mg and 1 mg

Launch of 2nd NDA Bortezomib for injection 3.5mg/1.4ml in US

Closure of Trading window

Vedanta Chairman Anil Agarwal reaffirmed the company's commitment to unlocking value, saying the four new companies that will emerge from the demerger, have the potential to grow into $100 billion companies each.

Execution of binding term sheet with mAbTree Biologics AG

Domestic markets closed slightly lower last week amid mixed global cues. Shares of Dr Reddy’s, Shilpa Medicare, and Tata Motors will be in focus today due to major developments. GR Infraprojects emerged as the selected bidder for an NHAI project worth Rs 4,263 crore.

USFDA Inspection at Unit 2 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited.

Intimation for participation in investor conference

Tata Power's arm Tata Power Renewable Energy has signed a memorandum of understanding (MoU) with the government of Andhra Pradesh to collaborate on renewable energy projects in the state.

USFDA Inspection at Unit - 1 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited

Transcript -Q3 FY 25

SEC - CDSCO Approval of Phase 3 Clinical Trial and Recommendation for grant of Marketing Approval for Shilpa''s IND Nor -Ursodeoxycholic acid Tablets.

Audio Recording of the conference call held on Tuesday, 11 2025

Revised Investor presentation

Investor presentation for the quarter ended 31st December, 2024

Integrated filing

Unaudited financial results for the quarter ended 31st December, 2024

BM outcome

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q3 and 9M/FY2024-25 Conference Call, which is to be held on Tuesday, February 11, 2025 at 11:00 AM IST.

SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 ,inter alia, to consider and approve The Meeting of Board of Directors of the Company will be held on Monday, 10 February, 2025 to inter alia consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December, 2024.In terms of the Code of Conduct for Prevention of Insider Trading in Securities of the Company, the TradingWindow has been closed with effect from 1 January, 2025 and remains closed upto 48 hours after the declaration of Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December, 2024

Shilpa Pharma Lifesciences Limited, received CEP from EDQM for API, Teriflunomide

Rejection letter from BSE for reclassification of Mr. Suraj Kumar Innani and Mrs. Priya Innani from Promoter/Promoter group to Public category

Rejection letter from NSE on reclassification of Mr. Suraj Kumar Innani and Mrs. Priya Innani from promoter/promoter group to public category

Compliance certificate under Reg 74(5) of SEBI (DP) Regulations 2018

Europe Approval for Tadalafil Orodisperible films

Closure of Trading Window

Eurasia (EAEU) GMP Approval of Shilpa Medicare Ltd, Unit IV , Jadcherla, Telangana and Unit VII Nacharam, Hyderabad, Telangana

Europe GMP Certificate for Shilpa Medicare Limited, Unit VII, Nacharam, Hyderabad from EMA, Austria

USFDA Approval of NDA - Imatinib Oral Solution

Indian Regulatory Authority - SEC approval for conducting Phase III clinical trials for Recombinant Human Albumin (eHA) 20%

Transcript Q2-H1-FY24-25

Shilpa Pharma Lifesciences Limited received CEP from EDQM for API , Nifedipine